| Literature DB >> 32830316 |
Dong Zhu1,2, Qunye Tang1,2, Baixue Yu1,3, Mei Meng1,3, Wenjie Liu1,3, Jiawei Li1,2, Tongyu Zhu1,2, Paul M Vanhoutte4, Susan W S Leung4, Yi Zhang1,3, Yi Shi1,3.
Abstract
BACKGROUND ANDEntities:
Keywords: IFN-γ; JNK; MHC Class II transactivator; TNF-α; glomerular endothelial cell; major histocompatibility complex; nephrectomy
Mesh:
Substances:
Year: 2020 PMID: 32830316 PMCID: PMC7589013 DOI: 10.1111/bph.15237
Source DB: PubMed Journal: Br J Pharmacol ISSN: 0007-1188 Impact factor: 8.739
Antibody information
| Antibody | Company | Catalogue and RRID | Application |
|---|---|---|---|
| APC Cy7 CD3 | BD Biosciences (San Jose, CA, USA) | 561042 | FACS, Cell surface (1:100) |
| RRID:AB_2034003 | |||
| PE Cy7 CD3 | BD Biosciences (San Jose, CA, USA) | 552774 | FACS, Cell surface (1:100) |
| RRID:AB_394460 | |||
| FITC CD4 | BD Biosciences (San Jose, CA, USA) | 557307 | FACS, Cell surface (1:100) |
| RRID:AB_396633 | |||
| PerCP CD8 | BD Biosciences (San Jose, CA, USA) | 553036 | FACS, Cell surface (1:100) |
| RRID:AB_394573 | |||
| PE CD25 | BD Biosciences (San Jose, CA, USA) | 553075 | FACS, Cell surface (1:100) |
| RRID:AB_394605 | |||
| Alexa Fluor@700 Foxp3 | BD Biosciences (San Jose, CA, USA) | 560401 | FACS, Intracellular (1:100) |
| RRID:AB_1645201 | |||
| PE IL‐5 | BD Biosciences (San Jose, CA, USA) | 562049 | FACS, Intracellular (1:100) |
| RRID:AB_10894193 | |||
| PE Cy7 IL13 |
| 25‐7133‐80 | FACS, Intracellular (1:100) |
| RRID:AB_2573529 | |||
| BV421 IL‐17 | BD Biosciences (San Jose, CA, USA) | 563354 | FACS, Intracellular (1:100) |
| RRID:AB_2687547 | |||
| BV711 IFN‐γ | BD Biosciences (San Jose, CA, USA) | 564336 | FACS, Intracellular (1:100) |
| RRID:AB_2738752 | |||
| APC TNF‐α | BD Biosciences (San Jose, CA, USA) | 561062 | FACS, Intracellular (1:100) |
| RRID:AB_2034022 | |||
| APC CD31 | BD Biosciences (San Jose, CA, USA) | 551262 | IF (1:20) FACS, Cell surface (1:100) |
| RRID:AB_398497 | |||
| BV421 CD31 | BD Biosciences (San Jose, CA, USA) | 562939 | FACS, Cell surface (1:100) |
| RRID:AB_2665476 | |||
| FITC H‐2K(d) | BD Biosciences (San Jose, CA, USA) | 562003 | FACS, Cell surface (1:100) |
| RRID:AB_10896664 | |||
| PerCP‐Cy I‐A/I‐E | BD Biosciences (San Jose, CA, USA) | 562363 | FACS, Cell surface (1:100) |
| RRID:AB_11153297 | |||
| PE CD86 | BD Biosciences (San Jose, CA, USA) | 561963 | FACS, Cell surface (1:100) |
| RRID:AB_10896971 | |||
| FITC CD80 | BD Biosciences (San Jose, CA, USA) | 561954 | FACS, Cell surface |
| RRID:AB_10896321 | (1:100) | ||
| BV510 CD45 | BD Biosciences (San Jose, CA, USA) | 563891 | FACS, Cell surface |
| RRID:AB_2734134 | (1:100) | ||
| CIITA | Abcam ( | ab117598 | WB, 123 kDa (1:1,000) |
| RRID:AB_10902499 | |||
| MHC I | Abcam ( | ab15681 | IF (1:50) IHC (1:200) |
| RRID:AB_302030 | |||
| MHC I + HLA B | Abcam ( | ab110645 | WB, 40 kDa (1:1,000) |
| RRID:AB_10859600 | |||
| MHC Class II | Abcam ( | ab55152 |
IF (1:50) IHC (1:200) WB, 54 kDa (1:1,000) |
| RRID:AB_944199 | |||
| MICA | Abcam ( | ab62540 |
IF (1:50) IHC (1:200) WB, 43 kDa (1:1,000) |
| RRID:AB_956135 | |||
| Phospho‐SAPK/JNK | Cell Signaling Technology ( | 4668 | WB, 54 and 46 kDa (1:1,000) |
| RRID:AB_823588 | |||
| SAPK/JNK | Cell Signaling Technology ( | 9252 | WB, 54 and 46 kDa (1:1,000) |
| RRID:AB_2250373 | |||
| Phospho‐NF‐κB p65 (Ser536) | Cell Signaling Technology ( | 3033 | WB, 65 kDa (1:1,000) |
| RRID:AB_331284 | |||
| NF‐κB p65 | Cell Signaling Technology ( | 8242 | WB, 65 kDa (1:1,000) |
| RRID:AB_10859369 | |||
| GAPDH | Millipore ( | MAB374 | WB, 38 kDa (1:2,000) |
| RRID:AB_2107445 |
FIGURE 1Mice subjected to 5/6 nephrectomy exhibit chronic inflammation in the cortex of remnant kidneys and increase MHC protein in glomeruli, 4 weeks after the surgery. (a) Isolated glomeruli under microscopy (left, low resolution; right, high resolution). (b) Glomeruli count in the kidney of 2K and 5/6Nx mice. n = 9; * P < 0.05, significantly different from the control 2K mice. (c) Levels of inflammatory cytokines in the kidney of 2K and 5/6Nx mice. n = 5; * P < 0.05, significantly different from the control 2K mice. (d–i) Presence of MHC molecule complex in glomeruli of 2K and 5/6Nx. Presence of MHC I (d), MICA (f), and MHC II (h) by immunohistochemistry staining. Presence of MHC I (e), MICA (g), MHC II (i), and CD31+ endothelial cells by immunofluorescent examination
FIGURE 2Allograft lymphocyte transfer deteriorates renal function in 5/6Nx mice. (a) Protocol for the total body irradiation and lymphocyte transfer in mice subjected to 5/6 nephrectomy. (b) Serum levels of creatinine. (c) CD3 T lymphocytes and subgroups in the kidney after total body irradiation and lymphocyte transfer. (d) Morphological changes in the kidney after lymphocyte transfer. n = 5–6; * P < 0.05, significantly different from control 2K mice; # P < 0.05, significantly different from 5/6Nx mice; $ P < 0.05, significantly different from 5/6Nx mice subjected to irradiation
FIGURE 3The up‐regulated MHC II protein is mainly expressed in CD31+ endothelial cells. (a) The presence of CD31+ endothelial cells in the kidney after lymphocyte transfer (upper: absolute value; lower: percentage value when normalized to the total examined cells measured by FACS). (b) Quantification of MHC II+ (upper), CD80+ (middle), and CD86+ (lower) signals in the CD31+ group. (c) Quantification of MHC II+ (upper), CD80+ (middle), and CD86+ (lower) signals in the CD31− group. (d) The presences of MHC II+, CD80+, and CD86+ signals in the CD31+ group measured by FACS. (e) The presences of MHC II+, CD80+, and CD86+ signals in the CD31− group measured by FACS. n = 5–6; * P < 0.05, significantly different from control 2K mice
FIGURE 4TNF‐α and IFN‐γ, but not TGF‐β1, increase MHC proteins in HGECs, but not in HAECs. (a) Representative western blots of MHC I, MICA, and MHC II proteins in HAECs (left) and HGECs (right), after 72‐h stimulation with TNF‐α (3 ng·ml−1), TGF‐β1 (5 ng·ml−1), or IFN‐γ (10 ng·ml−1). Densitometric quantification of MHC I (b), MICA (c), and MHC II (d) protein in HGECs (n = 5). * P < 0.05, significantly different from cells under control condition
FIGURE 5IFN‐γ (a) and TNF‐α (b) regulate MHC protein differently. (a) (left) Representative western blots of MHC I, MICA, MHC II, phosphorylated p65 of NF‐κB, total p65 NF‐κB protein, phosphorylated MAPK–JNK, total MAPK–JNK, and GAPDH protein in HGECs when stimulated with IFN‐γ (10 ng·ml−1). (a) (right) Densitometric quantification of MHC I, MICA, MHC II, phosphorylated p65 of NF‐κB, total p65 NF‐κB protein, phosphorylated MAPK–JNK, and total MAPK–JNK in HGEC when stimulated with IFN‐γ. n = 5; * P < 0.05, significantly different from cells under control condition. (b) (left) Representative western blots of MHC I, MICA, MHC II, phosphorylated p65 of NF‐κB, total p65 NF‐κB protein, phosphorylated MAPK–JNK, total MAPK–JNK, and GAPDH protein in HGECs when stimulated with TNF‐α (3 ng·ml−1). (b) (right) Densitometric quantification of MHC I, MICA, MHC II, phosphorylated p65 of NF‐κB, total p65 NF‐κB protein, phosphorylated MAPK–JNK, and total MAPK–JNK in HGEC when stimulated with TNF‐α. n = 5; * P < 0.05, significantly different from cells under control conditions
FIGURE 6(a) Protocol of lymphocyte migration in HGECs stimulated with TNF‐α (3 ng·ml−1) or IFN‐γ (10 ng·ml−1). (b) Lymphocyte count, in the absence of PHA, in the lower chamber containing freshly changed medium. (c) Lymphocyte count, in the presence of PHA, in the lower chamber containing freshly changed medium. (d) Lymphocyte count, in the absence of PHA, in the lower chamber containing 3‐day experimental medium. (e) Lymphocyte count, in the presence of PHA, in the lower chamber containing 3‐day experimental medium. (f) Lymphocyte count in the lower chamber after IFN‐γ stimulation during 72 h. (g) Lymphocyte count in the lower chamber after TNF‐α stimulation during 72 h. n = 5; * P < 0.05, significantly different from with cells under control conditions; # P < 0.05, significantly different from cells under the same condition, either with IFN‐γ or TNF‐α, respectively
FIGURE 7Inhibition of MAPK–JNK partly restores renal function in 5/6Nx mice. (a) Serum levels of creatinine. (b) Quantification of MHC II+ (upper), CD80+ (middle), and CD86+ (lower) signals in the CD31+ group in 5/6Nx mice treated with JNK inhibitors. (c) Quantification of MHC II+ (upper), CD80+ (middle), and CD86+ (lower) signals in the CD31− group in 5/6Nx mice treated with JNK inhibitors. (d) The presence of MHC II+, CD80+, and CD86+ signals in the CD31+ group measured by FACS in 5/6Nx mice treated with JNK inhibitors. (e) The presence of MHC II+, CD80+, and CD86+ signals in the CD31− group by FACS in 5/6Nx mice treated with JNK inhibitors. n = 9–10; * P < 0.05, significantly different from control mice (2K); # P < 0.05, significantly different from 5/6Nx mice. (f) Quantification of TNF‐α, IFN‐γ, IL‐5, IL‐13, and IL‐17 in CD3+ lymphocytes. n = 5; * P < 0.05, significantly different from control mice (2K); # P < 0.05, significantly different from 5/6Nx mice